GU CANCERS SYMPOSIUM 2024 ROUNDTABLE DISCUSSION:Contact-2
OR
Chair
Dr. Nazanin Fallah-Rad
Panelists
Dr. Sebastien Hotte
Dr. Maria Jiang
This program has been made possible through unrestricted support from EMD Serono & Ipsen
Studies/trials discussed:
- Contact 2 Study
- CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
